You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
龍津藥業(002750.SZ)上半年淨利潤跌87.73%至134.01萬元
格隆匯 08-25 18:08

格隆匯8月25日丨龍津藥業(002750.SZ)披露2019年半年度報告,實現營業總收入1.31億元,同比減少21.77%;歸屬於上市公司股東的淨利潤134.01萬元,同比減少87.73%;歸屬於上市公司股東的扣除非經常性損益後的淨虧損78.17萬元,同期錄得淨利潤58.62萬元;基本每股收益0.0033元。

報告期內因國家醫保控費、處方限制等政策持續推進,導致公司部分銷售區域、銷售終端銷售量下滑,致使公司營業利潤、利潤總額、歸屬於上市公司股東的淨利潤等財務指標有較大幅度的下滑。

報告期內,公司通過多種方式提高管理效率、降低管理成本,並啟動"見龍計劃"後備人才培養儲備項目。公司對製劑生產線停產進行升級改造順利完成,製劑生產線可以承擔大規格產品的生產任務,並完成注射用比伐蘆定、注射用生長抑素等大規格產品的生產,公司生產和質量體系在報告期內也順利通過雲南省藥品監督管理局的GMP飛行檢查。已有生產批件的注射用降纖酶、注射用生長抑素、注射用甲硫氨酸維B1等產品已進入穩定性考察階段,預計下半年可向國家藥監局提交注射用生長抑素增加規格申請資料。

在藥品研發方面,報告期內,公司取得2項發明專利授權、提交3項發明專利申請;在研品種方面,注射用比伐蘆定已完成中試,進入穩定性考察階段;替格瑞洛片已完成工藝等小試研究,將開展中試。公司通過仿製藥、創新藥等多種途徑,選取具有競爭優勢的特色藥品,依託龍津康佑、中科龍津等研發型平台,藉助優先審評、MAH制度等政策紅利,儲備具有市場前景的品種。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account